Sichenzia Ross Friedman Ference LLP Represents Amarantus BioScience Holdings, Inc. in $5.5M Registered Direct Offering and Private Placement
October 1, 2015 — New York, NY – Press Release – Nationally recognized securities and corporate law firm Sichenzia Ross Friedman Ference LLP (“SRFF”) is pleased to announce that the Firm has represented Amarantus Bioscience Holdings, Inc. (OTCQX: AMBS), a biotechnology company developing therapeutic and diagnostic product candidates for orphan indications and neurology in a registered direct offering where Amarantus issued $2.75 million of newly designated Series H convertible preferred stock and warrants. Additionally, SRFF represented Amarantus in a concurrent private placement where the Company issued $2.75 million in secured debt and warrants. At closing, the Company simultaneously repurchased all of the remaining 1,260 outstanding Series G convertible shares, having a face value of $6,300,000, and 212,087 common shares held by Discover Growth Fund at closing, for a total of $4.75 million in cash.
The Sichenzia Ross Friedman Ference LLP team was led by Partners Jeffrey Fessler and Marcelle Balcombe.
Visit SRF's LinkedIn page
Latest posts by Sichenzia Ross Ference LLP (see all)